Mirena (Levonorgestrel)

Levonorgestrel is released directly into the uterine cavity, where it thickens cervical mucus, suppresses the growth of the endometrium, and often inhibits ovulation. These actions together prevent sperm from reaching an egg and reduce the likelihood of implantation, while also decreasing menstrual flow.

Mirena is supplied as a single 52 mg intrauterine system that delivers a low, steady dose of levonorgestrel over five years. The exact release rate is set by the manufacturer, and the prescribing clinician determines suitability and timing of insertion and removal.

Mirena must not be used in women who are pregnant; insertion is contraindicated if pregnancy is confirmed. For breastfeeding mothers, the device can be inserted after delivery and is generally considered compatible with lactation, but clinicians should discuss individual risks and benefits with the patient.

To place an order, submit an enquiry on the Mirena product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Mirena contains 52 mg of levonorgestrel and is approved for up to five years of use, offering a higher hormone dose than some smaller IUDs such as Kyleena. This higher dose can result in more pronounced reduction of menstrual bleeding, while still providing reliable contraception. Choice of device depends on individual bleeding patterns, uterine size and clinician preference.

Mirena should be stored at ambient temperature, preferably below 25 °C, in its original sealed packaging. It must be protected from moisture and direct sunlight. The device should be handled only by trained healthcare professionals during insertion and removal to maintain sterility and device integrity.

Mirena is inserted by a qualified clinician into the uterine cavity using a specially designed inserter. The procedure is performed in a clinical setting, typically after confirming the patient is not pregnant and after a brief pelvic examination. Once placed, the device remains in situ for up to five years unless removal or replacement is required earlier.

Serious risks include uterine perforation during insertion, expulsion of the device, pelvic inflammatory infection, ectopic pregnancy if conception occurs, and rare cases of device migration to adjacent organs. Patients should be instructed to seek immediate medical attention for severe abdominal pain, abnormal bleeding or signs of infection.

Mirena is contraindicated in women with active pelvic infection, unexplained vaginal bleeding, known or suspected pregnancy, uterine anomalies that prevent proper placement, or a history of hypersensitivity to levonorgestrel. It should also be avoided in patients with certain cancers or severe liver disease, and clinicians should assess each individual’s medical history before prescribing.